274 related articles for article (PubMed ID: 12661569)
1. Atrial fibrillation--rate versus rhythm control.
Manning WJ
N Engl J Med; 2003 Mar; 348(13):1284-6; author reply 1284-6. PubMed ID: 12661569
[No Abstract] [Full Text] [Related]
2. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Selçuk H; Selçuk MT; Maden O
Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
[TBL] [Abstract][Full Text] [Related]
3. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
Mant JW
Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
[No Abstract] [Full Text] [Related]
4. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
Hu D; Sun Y
J Am Coll Cardiol; 2008 Sep; 52(10):865-8. PubMed ID: 18755352
[No Abstract] [Full Text] [Related]
5. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
Hylek EM
Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
[No Abstract] [Full Text] [Related]
6. The need for new oral anticoagulants in clinical practice.
Hylek EM
J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):605-9. PubMed ID: 19571764
[TBL] [Abstract][Full Text] [Related]
7. [Thromboembolism in non-rheumatic atrial fibrillation].
Pengo V
Haematologica; 2001 Sep; 86(9 Suppl):5-11. PubMed ID: 11759619
[No Abstract] [Full Text] [Related]
8. Acute management of atrial fibrillation: Part II. Prevention of thromboembolic complications.
King DE; Dickerson LM; Sack JL
Am Fam Physician; 2002 Jul; 66(2):261-4. PubMed ID: 12152961
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolic events occur despite sinus rhythm maintenance in patients treated for atrial fibrillation: The Canadian Trial of Atrial Fibrillation experience.
Thibault B; Talajic M; Dubuc M; Guerra P; Gagné P; Roy D; Connolly S;
Can J Cardiol; 2004 Feb; 20(2):195-9. PubMed ID: 15010743
[TBL] [Abstract][Full Text] [Related]
10. Patient education series. Atrial fibrillation.
Adkins L
Nursing; 2007 Apr; 37(4):43-4. PubMed ID: 17413365
[No Abstract] [Full Text] [Related]
11. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
Själander A; Wallentin L; Rosenqvist M; Svensson P
Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
[No Abstract] [Full Text] [Related]
12. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.
Sherman DG; Kim SG; Boop BS; Corley SD; Dimarco JP; Hart RG; Haywood LJ; Hoyte K; Kaufman ES; Kim MH; Nasco E; Waldo AL;
Arch Intern Med; 2005 May; 165(10):1185-91. PubMed ID: 15911734
[TBL] [Abstract][Full Text] [Related]
13. Atrial fibrillation: goals of therapy and management strategies to achieve the goals.
Padanilam BJ; Prystowsky EN
Cardiol Clin; 2009 Feb; 27(1):189-200, x. PubMed ID: 19111774
[TBL] [Abstract][Full Text] [Related]
14. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study).
Friberg L; Hammar N; Ringh M; Pettersson H; Rosenqvist M
Eur Heart J; 2006 Aug; 27(16):1954-64. PubMed ID: 16847008
[TBL] [Abstract][Full Text] [Related]
15. [Stroke and other thromboembolic complications of atrial fibrillation. Part VI. Choice of optimal approach and drugs for prevention of stroke].
Preobrazhenskiĭ DV; Sidorenko BA; Kiktëv VG; Batyraliev TA; Pershukov IV
Kardiologiia; 2005; 45(1):84-93. PubMed ID: 15699946
[TBL] [Abstract][Full Text] [Related]
16. Prevention of thromboembolic complication in atrial fibrillation by using anticoagulants.
Wagh K; Vikhe VB; Kumar RS; Auti N; Jose M
J Assoc Physicians India; 2013 Dec; 61(12):894-5. PubMed ID: 24968545
[TBL] [Abstract][Full Text] [Related]
17. AFFIRM and RACE trials: implications for the management of atrial fibrillation.
Blackshear JL; Safford RE; ;
Card Electrophysiol Rev; 2003 Dec; 7(4):366-9. PubMed ID: 15071255
[TBL] [Abstract][Full Text] [Related]
18. Atrial fibrillation and anticoagulation.
Garnier LF; Rouesnel P; Espitalier F
Arch Mal Coeur Vaiss; 2004 Oct; 97(10):1001-5. PubMed ID: 16008178
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation in atrial fibrillation.
Huerta BJ; Lemberg L
Heart Lung; 1985 Sep; 14(5):521-3. PubMed ID: 3849534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
